X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Synaptogenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 19, 2023
Details:
By developing ovarian cancer vaccine that target alpha-lactalbumin and AMHR2-ED, immune system can destroy breast cancer cells and ovarian cancer cells, respectively, as they arise and ultimately prevent tumors from forming.
Lead Product(s): Ovarian Cancer Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Anixa Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the next 3-4 years.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AriBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
The investigational vaccine targets a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues but is present in the majority of triple-negative breast cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Anixa Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.
Lead Product(s): CYTO-200
Therapeutic Area: Gastroenterology Product Name: CYTO-200
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Cytocom
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 17, 2021
Details:
Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.
Lead Product(s): Melatonin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
